Figure 6.

Plasma concentration of ERr 731 metabolite and the pharmacogenomic profiles for ERα/β target genes and bioactive peptides in the hypothalamus of ERr 731-treated rats. (A) Rhaponticin metabolite was detected in the plasma of rats treated orally with 0.3–3 mg/kg/day ERr 731 for 14 days in study 2 and (B) 7 days in study 3. (C) E₂ treatment significantly upregulated ERα but not ERβ target genes in the hypothalamus of OVX rats, and the opposite effect was observed for ERr 731. (D) Neither E₂ nor ERr 731 modulated the expression of neurotrophic factors; however, an agouti-related peptide Agrp was significantly elevated following the OVX surgery and ERr 731 treatment abolished this response. Individual hypothalamic tissue samples (n = 6) were analyzed by fluorescent quenching (A,B) or qPCR (C,D), and the data were expressed as the mean ± SEM, * p < 0.05 and *** p < 0.001 vs. OVX control.